|
2008 2007 2006 2005 2003-2004 2001-2002 1999-2000 1998
1995-1997
Corporate History
The Lexicon story began in 1995 when the company was founded. From the start, the company was dedicated to defining gene function and has evolved over the years into a drug discovery and development company. The company went public in 2000 with one of the largest initial public offerings (IPO) in biotech history. The proprietary gene knockout technology used by the company was recognized in 2007 with a Nobel Prize in medicine. The company began with the initiation of one gene knockout and today has studied nearly 5,000 gene knockouts. Lexicon is now a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease and has multiple drug candidates in human clinical trials.
2008
Lexicon initiated formal preclinical development of LX7101, a new drug candidate for glaucoma. More > Pipeline.
Lexicon successfully completed Phase 1 clinical trials of LX1031, an oral drug candidate for irritable bowel syndrome. More > Pipeline.
Lexicon's drug candidate, LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome received Fast Track status from the FDA. More > Pipeline.
Lexicon's drug candidate, LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions shows positive results in Phase 1 clinical trial. More > Pipeline.
Lexicon initiated a Phase 1a clinical trial of LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. More > Pipeline.
back to top
2007
Lexicon submitted an IND application to the FDA for LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. More > Pipeline.
LX6171, an oral drug candidate for cognitive disorders, successfully completed Phase 1 clinical trials and commenced dosing in a Phase 2a clinical trial. More > Pipeline.
Lexicon completed initial Phase 1 clinical trials of LX1031, an oral drug candidate for irritable bowel syndrome. Additional Phase 1 dose escalation study with LX1031 planned to explore additional dosage parameters. More > Pipeline.
Lexicon submitted an IND application to the FDA for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions. More > Pipeline.
Inventors of the proprietary gene knockout technology used by Lexicon received the Nobel Prize in Medicine. Drs. Mario Capecchi, Martin Evans, and Oliver Smithies were awarded the Prize for their pioneering work in targeted mutagenesis in mammals. In awarding this prize, the Nobel committee recognized the tremendous utility of this technology stating that, “Almost every aspect of mammalian physiology can be studied by gene targeting.” and that, “[This] immensely powerful technology… [is] now being applied to virtually all areas of biomedicine – from basic research to the development of new therapies.”
Lexicon changed its name to Lexicon Pharmaceuticals, Inc. to reflect its focus on drug discovery and development activities related to its 10TO10 program. The 10TO10 program is an ongoing company initiative with the goal of advancing 10 drug candidates into human clinical trials by the end of 2010. Lexicon also changed its common stock ticker symbol on the Nasdaq Global Market to "LXRX."
back to top
2006
Lexicon initiated a Phase 1 clinical trial for LX6171, an orally delivered small molecule compound for cognitive disorders, following a Clinical Trial Authorization (CTA) filing with the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). More > Pipeline.
Lexicon submitted an IND application to the FDA for LX1031, an internally-developed small molecule compound for irritable bowel syndrome. More > Pipeline.
back to top
2005
Lexicon received a $35 million award from the Texas Enterprise Fund for the creation of a comprehensive knockout mouse embryonic stem cell library containing 350,000 cell lines. Lexicon created the library using its proprietary gene trapping technology for the Texas Institute for Genomic Medicine, a newly formed non-profit institute whose founding members are Texas A&M University, the Texas A&M University System Health Science Center and Lexicon.
Lexicon was awarded a three-year contract to provide selected knockout mouse lines and related phenotypic data to the United States National Institutes of Health (NIH).
back to top
2003 - 2004
Lexicon was added to the NASDAQ Biotechnology Index.
back to top
2001 - 2002
Lexicon established its small molecule drug discovery capabilities in Princeton, NJ by acquiring Coelacanth Corporation. Coelacanth was a privately-held company using proprietary chemistry technologies to rapidly discover new chemical entities for drug development.
Dr. K. Barry Sharpless, a co-founder of Coelacanth Corporation, won the 2001 Nobel Prize in Chemistry. From this research, Dr. Sharpless established “Click chemistry,” a set of powerful and reliable tools for the rapid synthesis of novel compounds that Lexicon utilizes in its drug discovery efforts.
Drs. Mario Capecchi, Martin Evans and Oliver Smithies, received the 2001 Albert Lasker Award for Basic Medical Research in honor of their pioneering work in the development of knockout mouse technology. The breakthrough discoveries made by these three distinguished scientists established a foundation for the gene targeting technology that Lexicon uses to validate drug targets in vivo.
Lexicon announced the Genome5000™ program - an initiative to determine the function of 5,000 genes for the discovery of new drug targets.
back to top
1999 - 2000
Lexicon completed one of the largest initial public offerings (IPO) in biotech history, raising $220 million on April 7, 2000. JP Morgan and Credit Suisse led the offering.
Lexicon announced the major expansion of its corporate headquarters in The Woodlands, Texas increasing its campus to 252,000 square feet. The expansion included a new laboratory facility for the company to accelerate its process to define the function of genes for drug discovery.
Lexicon launched its LexVision™ program to define the function of genes in the human genome for the development of new therapeutics. The LexVision program has resulted in the world's largest repository of gene function information derived from knockout mice.
back to top
1998
Lexicon completed institutional private financing of $32 million.
back to top
1995 - 1997
Lexicon invents a new gene trapping technology and establishes a large-scale mammalian knockout program.
Lexicon signs exclusive license for gene knockout technologies developed at the University of Utah and The Netherlands Cancer Institute.
Lexicon completed initial private investment of $7 million and began operations on September 25, 1995 in The Woodlands, Texas.
|
